# Tetronic® 1307-Based Polymeric Micelles and Thermoresponsive Gels for the Co-Delivery of Pentamidine and Miltefosine

**Authors:** Javier Carriles, Carlos Aydillo, Gregory N. Smith, Cécile A. Dreiss, Paul Nguewa, Gustavo González-Gaitano

PMC · DOI: 10.3390/pharmaceutics18020233 · 2026-02-12

## TL;DR

This study explores using a special polymer to deliver two antiparasitic drugs together in a way that could improve treatment and reduce side effects.

## Contribution

A novel co-delivery system using Tetronic® 1307 enables synergistic antiparasitic therapy with thermoresponsive gel formation.

## Key findings

- MF and PTM were successfully co-delivered using T1307-based micelles and gels.
- The drug combination showed synergistic effects against Leishmania major.
- Thermoresponsive gels formed at physiological temperatures, suitable for topical use.

## Abstract

Background: Pentamidine isethionate (PTM) and miltefosine (MF) are clinically relevant antiparasitic agents whose use is limited by toxicity, emerging resistance, and the lack of effective co-delivery strategies. Tetronic® 1307 (T1307), an amphiphilic and thermoresponsive block copolymer, was investigated as a carrier to enable their combination therapy. Methods: PTM and MF were formulated in T1307-based micelles and thermoresponsive gels. The systems were characterized by small-angle neutron scattering (SANS), dynamic light scattering (DLS), and nuclear magnetic resonance spectroscopy (NMR). Antiparasitic activity was evaluated against Leishmania major promastigotes. Results: MF formed stable micelles that efficiently incorporated PTM, generating a “drug-in-drug” architecture. While T1307 alone showed limited PTM loading, MF promoted mixed micelle formation and enhanced PTM incorporation. At physiological temperature and adequate copolymer concentrations, drug-loaded micelles formed thermoreversible gels suitable for topical application. The combined formulations preserved drug activity and exhibited synergistic effects against L. major. Conclusions: T1307 is a promising platform for the co-delivery of PTM and MF, enabling synergistic combination therapy and thermoresponsive gel formation with potential to reduce systemic toxicity and improve treatment administration.

## Linked entities

- **Chemicals:** Pentamidine isethionate (PubChem CID 8813), miltefosine (PubChem CID 3599)

## Full-text entities

- **Genes:** CALM1 (calmodulin 1) [NCBI Gene 801] {aka CALML2, CAM2, CAM3, CAMB, CAMC, CAMI}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, MAPK9 (mitogen-activated protein kinase 9) [NCBI Gene 5601] {aka JNK-55, JNK2, JNK2A, JNK2ALPHA, JNK2B, JNK2BETA}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, S100A1 (S100 calcium binding protein A1) [NCBI Gene 6271] {aka S100, S100-alpha, S100A}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}
- **Diseases:** neglected tropical disease (MESH:D058069), nausea (MESH:D009325), vomiting (MESH:D014839), hemolytic (MESH:D006461), visceral leishmaniasis (MESH:D007898), hypotension (MESH:D007022), mitochondrial dysfunction (MESH:D028361), skin lesions (MESH:D012871), Parkinson's disease (MESH:D010300), pain (MESH:D010146), prostate cancer (MESH:D011471), injury to (MESH:D014947), glucose metabolism disorders (MESH:D044882), hepato-nephrotoxicity (MESH:D015211), leishmaniasis (MESH:D007896), cancer (MESH:D009369), diabetes (MESH:D003920), Alzheimer's disease (MESH:D000544), ovarian cancer (MESH:D010051), acute hepatic injury (MESH:D056486), breast and colon cancer (MESH:D001943), CL (MESH:D016773), glioblastoma (MESH:D005909), vector-borne disease (MESH:D000079426), muscular dystrophy (MESH:D009136), endometrial cancer (MESH:D016889), ulcers (MESH:D014456), cytotoxicity (MESH:D064420), gastrointestinal disturbances (MESH:D005767), cardiovascular complications (MESH:D002318)
- **Chemicals:** PTM (MESH:D010419), water (MESH:D014867), polymethacrylate (MESH:C030613), D2O (MESH:D017666), ceramide (MESH:D002518), hemin (MESH:D006427), cholesterol (MESH:D002784), adenine (MESH:D000225), SDS (MESH:D012967), Rh (MESH:D012238), biotin (MESH:D001710), formazan (MESH:D005562), chitosan (MESH:D048271), phosphate (MESH:D010710), sugar (MESH:D000073893), paraffin oil (MESH:C015418), saline (MESH:D012965), polymer (MESH:D011108), biopterin (MESH:D001708), EO (MESH:D005027), streptomycin (MESH:D013307), PEO (MESH:D011092), diamine (MESH:D003959), lipid (MESH:D008055), PLA (MESH:C033616), polystyrene (MESH:D011137), PO (MESH:C009068), polyamine (MESH:D011073), DMSO (MESH:D004121), PVDF (MESH:C024865), diacylglycerol (MESH:D004075), PPO (MESH:C012504), HEPES (MESH:D006531), penicillin (MESH:D010406), Pluronic F127 (MESH:D020442), sphingomyelin (MESH:D013109), deuterium (MESH:D003903), VMF-t (-), PC (MESH:D010713), hydrocarbon (MESH:D006838), PCL (MESH:C016240), MTT (MESH:C070243), ergosterol (MESH:D004875), MF (MESH:C039128), T1307 (MESH:C000610401)
- **Species:** Homo sapiens (human, species) [taxon 9606], Leishmania major (species) [taxon 5664]
- **Cell lines:** S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232), Lv39c5 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_B7Q6)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12944060/full.md

---
Source: https://tomesphere.com/paper/PMC12944060